Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Phase 2 Terminated 79 enrolled Spanish Group for Research in Neuroendocrine Tumors MFAR · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.

Timeline

Start: 2019-04-02
Primary completion: 2024-11-08
Completion: 2024-11-08

Outcome

Outcome not reported

Stopped: “In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.”

Publications

Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Alvarez-Escola C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yaya Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. Nat Commun. 2026 Apr 4;17(1):4891. doi: 10.1038/s41467-026-71155-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	—
Subject	Tremelimumab	Monoclonal antibody	75 mg	—